Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-sequencing of pretreatment AB1 (mesothelioma) and Renca (kidney cancer) tumours mice both respondant and non-respondant to immunotherapy with CTLA4 and PD-L1

ABSTRACT: Purpose: Cancer immunotherapy has shown outstanding results in the past few years. Specifically, antibodies targeting immune checkpoints can prolong survival in some patients with various cancer types. However, most patients do not respond, and it is not fully understood what biological processes determine an effective outcome. This lack of understanding hinders the development of rational combination treatments. Methods: Here, we analysed bulk RNAseq data obtained from pretreatment responding and non-responding tumour samples from mice treated with antibodies against CTLA4 and PD-L1. Results: We found that responsive tumours displayed an inflammatory gene expression signature which was consistent with positive upstream regulation by not only IFNγ/STAT1, but also TLR3 and negative regulation by IL-10. Our results identify a pre-treatment cellular microenvironment and molecular signature associated with benefit from immune checkpoint blockade that can be therapeutically attained to improve treatment efficacy.

ORGANISM(S): Mus musculus

PROVIDER: GSE117358 | GEO | 2019/07/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNA-sequencing of pretreatment AB1 (mesothelioma) and Renca (kidney cancer) tumours mice both respondant and non-respondant to immunotherapy with CTLA4 and PD-L1

Project description:RNA-sequencing of pretreatment AB1 (mesothelioma) and Renca (kidney cancer) tumours mice both respondant and non-respondant to immunotherapy with CTLA4 and PD-L1

| PRJNA481876 | ENA

Time-course bulk RNAseq and single-cell RNAseq of murine AB1 mesothelioma and Renca renal cancer following immune checkpoint therapy

Project description:The on/off dynamics of IFNβ signalling underlie the therapeutic response to immune checkpoint therapy in cancer in mice

2022-09-14 | GSE213296 | GEO

Qualitative changes in activated T cells induced by checkpoint blockade in vivo

Project description:Here we perform QuantSeq 3' mRNA sequencing of RNA extracted from flow sorted splenic T cell from Tg4 Nr4a3-Tocky Tiger mice that had been immunised with 80ug of 4Y MBP peptide for 24 hours. After 24 hours mice were re-stimulated with 8ug 4Y MBP in the presence of isotype, anti-PD1 or anti-Lag3 antibodies for 4 hours. The results show that anti-PD1 but not anti-Lag3 imparts a unique transcriptional signature on responding T cells, indicative of stronger TCR signalling.

2021-07-30 | GSE165818 | GEO

Transcriptomic analysis of transforming growth factor beta (TGF-beta)-responding SCC cells and Fc epsilon receptor I alpha (FceRIa)-positive macrophages

Project description:TGF-beta-responding SCC cells, a tumor-initiating cell population, show a unique gene expression signature, including antioxidant gene expression and IL-33 upregulation. IL-33-responding macrophages in SCC, which also express Fc epsilon receptor I alpha, show a gene expression signature that resembles alternatively-activated macrophages

2020-07-20 | GSE151783 | GEO

Gene expression data of multiple lesions of a melanoma patient

Project description:Treatment with antibodies targeting immune checkpoints and kinase inhibitors results in long lasting disease remission in a small fraction of melanoma patients. This outstanding patient showed a complete and durable response after Ipilimumab rechallenge. We studied microenvironment composition and the tumor evolution. Through gene expression profiling, we detailed the unique microenvironment characterizing this melanoma patient who experienced a complete response to a rechallange with Ipilimumab

2022-05-31 | GSE171484 | GEO

Comparison of Renca tumor cells growing intrakidney or subcutaneously

Project description:Tumors can occur in many sites in the body, but how tissues at different anatomical sites affect tumor microenvironments and their subsequent response to therapy is not known. Here we show that different tissues can cause the same tumor to develop fundamentally different microenvironments resulting in dramatic changes in responses to immunotherapy. Whereas established subcutaneous tumors could be eradicated in the majority of mice using a combination of three agonist antibodies, tumors in visceral organs responded much less. Orthotopic kidney tumors had a microenvironment with a higher frequency of alternatively-activated macrophages and their associated molecules. Neutralizing the CCL2 chemokine or IL-13 cytokine, important in macrophage biology led to a greatly improved therapeutic effect. Importantly, a significantly reduced therapeutic response of subcutaneous tumors was observed when visceral tumors were simultaneously present in the same mice. In this study we sought to compare gene expression of mouse renal cell carcinoma cells growing in the kidney to cells growing subcutaneously. Renca is a renal cell carcinoma cell line (Murphy and Hrushesky, 1973). To produce subcutaneous tumors, mice received 2 x 10^5 Renca. Orthotopic tumors were established by first surgically isolating the organ and then injecting 2 x 10^5 Renca cells intrakidney (IK) into the outer cortex of the kidney in 20 ul of PBS. Tumors were removed from mice 12 days after implantation, when approximately 20-30 mm2. Tumors were snap frozen on liquid nitrogen prior to processing for total RNA followed by analysis on Mouse Gene 1.0 chips.

2012-09-08 | GSE40679 | GEO

Foxp3 expression in macrophages associated with RENCA tumors in mice.

Project description: Not available

| S-EPMC4180934 | biostudies-literature

Comparison of Renca tumor cells growing intrakidney or subcutaneously

2012-09-08 | E-GEOD-40679 | biostudies-arrayexpress

Transcription profiling of human pretreatment glucocortocoid sensitive and resistant primary leukaemias

Project description:Drug resistance remains a major obstacle to successful cancer treatment. Here we use a novel approach to identify rapamycin as a glucocorticoid resistance reversal agent. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in Acute Lymphoblastic Leukemia (ALL) cells. The screen indicated the mTOR inhibitor rapamycin profile matched the signature of GC-sensitivity. We thus tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells, and found that it sensitized cells to glucocorticoid induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis, and that the combination of rapamycin and glucocorticoids has potential utility in ALL. Furthermore this approach represents a novel strategy for identification of promising combination therapies for cancer. Experiment Overall Design: primary acute lymphoblastic leukemia samples were determined to be sensitive or resistant to in vitro treatment with glucocorticoids. Samples were then hybrized to affymetrix microarrays

2009-04-04 | E-GEOD-5820 | biostudies-arrayexpress

Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST)

Project description:Gene expression profiling using oligonucleotide microarrays performed on tumor samples obtained before and after imatinib mesylate (IM) therapy. Rapid responding (to IM) samples were compared to non-responding/stable disease samples as measured by CT scan measurements to identify a gene signature that can predict rapid response to IM.

2009-11-24 | GSE15966 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data